Choice of pharmacotherapy for various clinical forms of dry eye disease

<p><strong>Purpose</strong>: to investigate therapeutic effectiveness of several new pharmacotherapeutic agents for dry eye disease (DED) of various severity and ethiological factors.<br /><strong>Methods</strong>: there were 72 patients under observation with dry eye disease divided into three groups. Group I-DED mild stage 1, Group II-DED stage 2, moderate stage with secondary damage after adenoviral eye infection. Group III-DED, stage 3, severe damage associated with meibomian gland dysfunction. Diagnostics — subjective symptoms, biomicroscopic data and diagnostic tests were assessed and scored: Schirmer test, Norn test, rose bengal and fluorescein staining, OCt assessment of tear meniscus, tear osmolar- ity measurement. the following agents were used as basis therapy in various algorithms: Visine Pure tears or Artificial tear, Hilabak, VitA-Pos and adjunctive anti-infective and anti-inflammatory therapies if needed.<br /><strong>Results</strong>: Positive therapeutic effect was achieved in all patients. Subjective symptoms and diagnostic test results improved from the first day.<br /><strong>Conclusion</strong>: Clinical signs improvement and positive trends in diagnostic test results were seen in all of the three groups of variousseverity and ethiology. there was an effort put in every group to personalize pharmacotherapies.